Seres Therapeutics (NASDAQ:MCRB) Downgraded to Sell Rating by StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

A number of other equities research analysts have also recently issued reports on MCRB. Chardan Capital reaffirmed a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Seres Therapeutics currently has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB opened at $0.88 on Wednesday. The stock has a market capitalization of $149.74 million, a P/E ratio of -3.81 and a beta of 2.06. The business has a 50-day moving average of $0.82 and a two-hundred day moving average of $0.90. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.05.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC boosted its holdings in Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares during the period. Providence Wealth Advisors LLC lifted its stake in shares of Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the period. State Street Corp lifted its stake in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares during the period. Point72 DIFC Ltd bought a new position in Seres Therapeutics during the second quarter valued at about $64,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Seres Therapeutics in the 2nd quarter valued at approximately $92,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.